Table of Contents
Introduction
The Global Pneumococcal Vaccines Market is expected to reach approximately USD 15.8 billion by 2034, growing from USD 8.6 billion in 2024. This growth reflects a compound annual growth rate (CAGR) of 6.3% during the forecast period. The market is witnessing steady expansion due to evolving public health policies, increasing immunization coverage in low-income countries, and recent technological advancements in vaccine formulation.
One of the major growth drivers is the revision of immunization guidelines. In October 2024, the U.S. Centers for Disease Control and Prevention (CDC) updated its recommendations to include pneumococcal vaccination for all adults aged 50 and above. Previously, this age group was not universally covered unless they had certain risk factors. The updated policy aims to enhance prevention in populations with higher disease incidence and is expected to significantly increase vaccination rates across this demographic. Similar guideline updates are expected globally, reinforcing market growth.
Demand from low-income and middle-income countries is another key factor. Countries like India, China, and Indonesia have integrated pneumococcal conjugate vaccines (PCVs) into their national immunization programs. This rollout is projected to contribute over 60 million additional doses globally in the coming years. Programs such as Gavi’s Advance Market Commitment (AMC), which has allocated USD 1.5 billion to subsidize vaccine procurement, are making vaccines affordable and encouraging wider adoption in underserved regions.
Technological innovations in vaccine development are also shaping market dynamics. New vaccines are being designed to offer broader protection against multiple serotypes. In 2024, Merck received U.S. FDA approval for Capvaxive, a vaccine targeting 21 strains of pneumococcal bacteria, specifically for adults aged 18 and older. Likewise, Vaxcyte is developing VAX-31, which has shown promising early results by eliciting strong immune responses against 31 serotypes in adults over 50. These innovations are expected to improve disease prevention and expand the addressable patient population.
In conclusion, the growth of the pneumococcal vaccines market is being driven by policy expansions, increasing demand in lower-income countries, and significant vaccine innovation. With strong support from global health organizations and continued technological progress, the sector is poised to play a crucial role in reducing the burden of pneumococcal diseases worldwide. These growth factors are expected to sustain the market’s upward trajectory through 2034.
Key Takeaways
- In 2023, the pneumococcal vaccines market earned US$ 8.6 billion and is projected to reach US$ 15.8 billion by 2033 at a 6.3% CAGR.
- Pneumococcal conjugate vaccines dominated the product type segment in 2023, holding a 62.5% share due to broader coverage and stronger immunological protection.
- Pharmacies accounted for 68.9% of vaccine distribution in 2023, making them the primary channel for pneumococcal vaccine administration globally.
- North America led the global pneumococcal vaccines market in 2023, capturing 39.4% of total revenue owing to advanced immunization programs and awareness.
Emerging Trends
- Broader Vaccine Coverage is Expanding Protection: New vaccines are being developed to cover more bacterial serotypes. In June 2024, Merck received FDA approval for its 21-valent pneumococcal conjugate vaccine, Capvaxive. This vaccine includes protection against eight additional serotypes not found in earlier versions. Another candidate, VAX-31 by Vaxcyte, is under trial and shows promise with coverage against 31 serotypes. These advancements aim to increase protection, especially in regions where non-vaccine serotypes are emerging. Broader coverage is essential to stay ahead of bacterial evolution and reduce the burden of pneumococcal disease globally.
- Vaccination Guidelines Have Been Expanded: The U.S. Centers for Disease Control and Prevention (CDC) updated its pneumococcal vaccine recommendations in October 2024. The new guideline includes all adults aged 50 and older, compared to the previous minimum age of 65. This change is expected to reduce the disease burden in middle-aged adults. It targets groups with increasing vulnerability, such as those with underlying health conditions. Expanded eligibility will also help increase vaccine uptake and improve community-level immunity, especially as newer vaccines offer broader protection.
- Falling Immunization Rates Are Raising Concerns: Some countries are experiencing a decline in pneumococcal vaccination rates. Australia, for example, reported a 20-year high in invasive pneumococcal disease cases during 2024. Health officials link this rise to lower vaccine uptake and the emergence of new bacterial strains. The data highlights the importance of maintaining high immunization coverage, even when vaccines are available. Public health campaigns and updated vaccine schedules may be required to rebuild trust, address hesitancy, and close immunization gaps across different population groups.
- Focus is Increasing on High-Risk Groups: There is a growing focus on vaccinating high-risk individuals, such as people with chronic illnesses like chronic obstructive pulmonary disease (COPD). These groups are more susceptible to severe pneumococcal infections. To improve protection, healthcare providers are using sequential vaccination strategies. These involve giving more than one type of pneumococcal vaccine to the same individual. The approach is designed to maximize immune response and ensure full serotype coverage. This trend supports personalized vaccination plans based on medical risk and immune status.
Use Cases
- Infant Immunization: Pneumococcal vaccines play a key role in protecting young children from serious infections. The CDC recommends a 4-dose schedule for all children under 5 years of age. These doses are given at 2, 4, 6, and 12–15 months. This routine helps protect against invasive pneumococcal disease, which can lead to pneumonia, blood infections, and meningitis. The introduction of this vaccination schedule has led to a sharp decline in pneumococcal infections among children. Early immunization is important because infants have weaker immune systems and are more likely to develop severe disease. Pediatricians and health departments continue to promote this vaccine as a standard part of early childhood healthcare.
- Adult Vaccination: Pneumococcal vaccination is now recommended for all adults aged 50 years and older. This is because the risk of severe illness increases with age. Older adults are more likely to develop pneumococcal pneumonia and bloodstream infections. Vaccination can help lower these risks and reduce hospitalizations. It is especially important for seniors with existing health conditions. Many public health programs now offer the vaccine through clinics, pharmacies, and hospitals. The CDC has updated its guidelines to expand vaccine access for this age group. This shift in policy is expected to improve long-term health outcomes and reduce the spread of disease among older populations.
- Protection for High-Risk Individuals: People with chronic health problems face higher risks from pneumococcal infections. These include those with diabetes, heart disease, asthma, or weak immune systems. For them, pneumococcal vaccines can prevent serious complications like pneumonia, sepsis, and meningitis. Vaccination is often advised during regular doctor visits or hospital stays. Patients with cancer or HIV also benefit greatly from this protection. The vaccine helps lower their chances of getting life-threatening infections. Healthcare providers regularly recommend pneumococcal vaccines as part of routine care for high-risk groups. This strategy supports overall disease control and protects individuals whose bodies cannot fight infections as well.
- Outbreak Prevention in Vulnerable Communities: Targeted vaccination campaigns are important in preventing outbreaks of pneumococcal disease. This is especially true in areas with low immunization coverage or limited healthcare access. Health authorities often focus on protecting elderly people, indigenous populations, and rural communities. For example, in Australia, a rise in pneumococcal cases led to updated vaccination programs. Newer vaccines with broader coverage were introduced to respond to emerging strains. These public health efforts can stop infections from spreading rapidly. Outreach programs, community clinics, and mobile units help deliver vaccines to those who need them most. These actions play a vital role in preventing regional health crises.
Conclusion
In conclusion, the pneumococcal vaccines market is expected to grow steadily due to expanded immunization policies, rising vaccine access in lower-income countries, and innovations in vaccine development. New recommendations for adult vaccination and increasing focus on high-risk groups are improving public health outcomes. At the same time, broader vaccine coverage is helping address emerging bacterial strains. While some regions face challenges with falling vaccination rates, public health efforts are actively working to rebuild trust and coverage. As global health organizations continue to support vaccination programs, the market is well positioned for long-term growth. Pneumococcal vaccines will remain essential tools in preventing serious infections and reducing disease burden across all age groups.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
